Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aixcrypto Holdings
Its shares trade under the ticker AIXC. It has been listed since 24 June 2015. In the fiscal year to 31 December 2021, it reported revenue of $5.7m and a net loss of $17.9m. At that date it held total assets of $22.8m and shareholders' equity of $16.6m.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California. The company went IPO on 2015-06-24. The firm is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jun 2015
- Employees
- 5
- Website
- qualigeninc.com ↗
Leadership
Pay as last reported
- Mr. Campbell BecherPresident, since 2024$88,000
- Mr. Kevin RichardsonCo-Chief Executive Officer, Director, since 2024$90,907
- Mr. Jiawei WangCo-Chief Executive Officer
- Mr. Koti MekaChief Financial Officer
- Mr. Chad ChenDirector
- Mr. Jay ShengDirector
- Mr. Graydon BenslerIndependent Director
- Mr. Kevin ChenIndependent Director
- Mr. Braeden LichtiIndependent Director$25,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Qualigen Therapeutics focuses on cancer and infectious disease therapeutics with AS1411 and ALAN pipeline products.
- FastPack diagnostic platform offers immunoassay testing with analyzer and disposable pouch system.
- Subsidiary Qualigen, Inc. supports development and commercialization of therapeutic products.
Weaknesses
- 5 full-time employees limit operational capacity and R&D scale for biotechnology development.
- IPO on 24 June 2015 indicates limited market history and potential investor skepticism.
- Los Angeles headquarters may face competition from biotech hubs like San Francisco.
Opportunities
- Expanding FastPack System usage in diagnostic markets for cancer and infectious disease testing.
- Commercializing ALAN-CE and ALAN-RE for enhanced contrast and radiation therapy applications.
- Growing biotechnology sector in Health Care industry with increased funding opportunities.
Threats
- Biotechnology sector competition from established firms with larger R&D budgets.
- Regulatory challenges in FDA approval processes for new cancer therapeutics.
- Market volatility affecting biotech IPOs and investor confidence in 2015.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.